Related Experiment Videos
Developmental ototoxicity
1Baylor College of Medicine, Houston, Texas.
Abstract:
The aminoglycoside antibiotics are active bactericidal agents used for the treatment of tuberculosis and gram-negative bacterial infections. Well over 2 million patients per year receive aminoglycosides; however, a major limitation to their use is ototoxicity (cochleotoxicity and vestibulotoxicity), nephrotoxicity, and neuromuscular blockade. Ototoxicity can result from aminoglycoside administration to any patient population, including adults, fetuses, and preterm and full-term neonates. Preterm infants and experimental animals are hypersensitive to aminoglycoside ototoxicity during the period of anatomic and functional maturation of the inner ear. Developing animals, including humans, are also hypersensitive to loop diuretics and especially to the combination of loop diuretics and aminoglycosides. Ototoxicity depends upon several factors in addition to age, including patient population, dose and duration of therapy, genetic and pharmacokinetic factors, and the particular aminoglycoside used. The molecular mechanisms of developmental hypersensitivity have not yet been determined.
Insights
Aminoglycoside antibiotics, crucial for bacterial infections, can cause ototoxicity, especially in developing infants. Further research is needed to understand the molecular mechanisms of this hypersensitivity.
Area of Science:
- Pharmacology
- Toxicology
- Oto-toxicology
Background:
- Aminoglycoside antibiotics are vital for treating tuberculosis and Gram-negative bacterial infections, with over 2 million patients annually.
- A significant drawback of aminoglycosides is their potential for ototoxicity (cochleotoxicity and vestibulotoxicity), nephrotoxicity, and neuromuscular blockade.
- Ototoxicity can affect all patient groups, including adults, fetuses, and neonates.
Purpose of the Study:
- To review the factors contributing to aminoglycoside-induced ototoxicity.
- To highlight the heightened sensitivity of preterm infants and developing animals to aminoglycoside ototoxicity.
- To discuss the ototoxic risks associated with combined aminoglycoside and loop diuretic therapy.
Main Methods:
- Literature review of studies on aminoglycoside toxicity.
- Analysis of factors influencing ototoxicity, including age, dose, duration, genetics, and drug class.
- Examination of developmental hypersensitivity in animal models and human neonates.
Main Results:
- Preterm infants and experimental animals exhibit hypersensitivity to aminoglycoside ototoxicity during inner ear maturation.
- Developing organisms show increased susceptibility to loop diuretics and a synergistic ototoxic effect when combined with aminoglycosides.
- Ototoxicity is multifactorial, influenced by age, patient population, dosage, duration, genetics, and specific aminoglycoside used.
Conclusions:
- Aminoglycoside ototoxicity is a significant clinical concern across diverse patient populations.
- Developmental hypersensitivity to aminoglycosides, particularly in neonates, warrants careful consideration.
- The precise molecular mechanisms underlying developmental hypersensitivity to aminoglycosides remain undetermined and require further investigation.